Table 1: Neutralizing activity of sequential serum samples against autologous envelope was modest

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Day post-transplant | -360 | 6 | 12 | 15 | 63 | 76 | control b |
| *Autologous Env: c* |  |  |  |  |  |  |  |
| A10 | <20d | <20 | 129 | 114 | 52 | <20 | <20 |
| B9 | <20 | <20 | 54 | 91 | 30 | <20 | <20 |
| C1 | <20 | <20 | 158 | 158 | 29 | 23 | <20 |
| D2A | <20 | <20 | 104 | 138 | 56 | 21 | <20 |
| *Heterologous Env: e* |  |  |  |  |  |  |  |
| ZM233M.PB6 | <20 | <20 | 82 | 96 | <20 | <20 | <20 |
| 93MW965.26 | 129 | 60 | 162 | 391 | 1488 | 1232 | <20 |
| VSV | <20 | <20 | 47 | <20 | <20 | <20 | <20 |

*a* Titres are expressed as the reciprocal dilution of serum required to reduce infectivity by ≥50% (IC50). *b* pooled Normal (HIV-seronegative) Human Sera. *c* The autologous *envs* were cloned from peak-vireamia (day +13). *d* <20, less than 50% reduction of infection was observed with the highest serum input assayed (1:20 dilution). *e* ZM233M.PB6, tier 2 clade C Env; 93MW965.26, tier 1 clade C Env; VSV, Vesicular Stomatitis Virus envelope glycoprotein.